Unfortunately people can't have it both ways: either the Phase 1 is just about safety or the spleen lesion PR was pure pump by a unprofessional OTC CEO.
But as I've stated repeatedly, K is totally irrelevant for shareholders and really shouldn't be part of any discussion about current or future share price (at least within the next three years).